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INTRODUCTION
Hepatocellular adenoma (HCA) is a benign liver tumor composed of hepatocytes. 1 HCA represents a heterogeneous entity, and is subclassified into four groups according to genotype and phenotype: hepatocyte nuclear factor (HNF) 1α-inactivated HCA, β-catenin-activated HCA, inflammatory HCA, and unclassified HCA. 1 Theses subtypes vary greatly in their clinical and pathological features. Identifying the HCA subtype is important because it represents a way to understand the prognosis of HCA in terms of hepatocellular carcinoma (HCC) transformation. We present a case of β-catenin-activated HCA and discuss the histopathological findings with a review of the literature.
CASE SUMMARY
A 39-year-old man was admitted to our hospital to evaluate an asymptomatic hepatic mass detected incidentally during a health checkup. The patient did not have a history of alcoholism, androgenic steroid use, or metabolic syndrome. The subject's body mass index (BMI, kg/m 2 ) was 20.7 (normal range, 18.50-24.99 kg/m 2 ).
Serum aspartate aminotransferase was 21 IU/L (normal range, 12-33 IU/L), alanine aminotransferase was 14 IU/L (normal range, 5-35 IU/L), and gamma-glutamyl transferase (GGT) was 31 IU/L (normal range, 12-73 IU/L). Other liver function tests were within normal limits. Hepatitis B virus surface antigen was negative, and the levels of tumor markers were all within normal ranges. Magnetic resonance imaging demonstrated a lobulated contoured hepatic mass located in segment VI that showed iso-intensity on T1-weighted images, heterogeneous high-intensity on T2-weighted images, and a focal signal drop, particularly at the periphery, on fat-suppressed T2-weighted images (Fig. 1A) , suggesting hepatocellular adenoma. A laparoscopic wedge resection was performed.
PATHOLOGICAL FINDINGS
A 5.2×3.6 cm sized, homogeneous, green colored hepatic mass was observed on the cut section (Fig. 1B) . The margins of the mass were relatively well-defined but not encapsulated. The mass was microscopically composed of benign hepatocytes arranged in one or two thick irregular cell plates with sharp demarcation from the surrounding non-tumoral liver ( Fig. 2A) . The background liver was normal. Other characteristic pathological features of this mass included peliosis (Fig. 2B) , sinusoidal dilatation and inflammatory infiltrates (Fig. 2C ), diffuse steatosis (Fig. 2D) , cytoplasmic bile pigment and feathery degeneration of hepatocytes (Fig. 2E) merous unpaired arteries, and bile duct loss. An occasional pseudoglandular growth pattern and cytologic atypia were also observed (Fig. 2F) . Immunohistochemistry revealed that the tumor cells were positive for glutamine synthetase (GS) in a diffuse pattern (Fig. 3A) and showed aberrant cytoplasmic and nuclear β-catenin expression (Fig. 3B) . The tumor cells were negative for two inflammation-related proteins, serum amyloid A and C reactive protein (SAA/CRP) and also negative for glypican 3. The final diagnosis was β-catenin-activated HCA based on the histological and immunohistochemical findings. No obvious recurrence of the 
DISCUSSION
HCA is a rare benign liver tumor (solitary or multiple) that most frequently develops in young women who are using oral contraceptives (OC). HCA is rare in children, men, and the elderly. 1 Most men developing HCA have been users of anabolic steroids for bodybuilding. 1, 2 Patients taking androgens for Fanconi anemia or acquired aplastic anemia are also at risk. 2 Obesity and alcohol intake have recently been shown to be risk factors for developing inflammatory HCA. 3 HCA can also occur in specific settings such as metabolic disease (glycogenosis, tyrosinemia, or galactosemia) but rarely in association with polycystic ovary syndrome or advanced-stage fatty liver disease. 4 Some small HCA may regress after withdrawal of OC or after menopause; however, they usually remain stable, or increase in size. Clinically significant hemorrhaging is observed in 20-25% of cases. Malignant transformation to HCC is rare but well-documented. [5] [6] [7] HCA are classified into three main subgroups according to genotype: (1) inactivating mutations in the HNF 1α gene, (2) activating mutation in the CTNNB1 gene that encodes β-catenin, and (3) activation of signal transducers and activators of transcription type 3 in the absence of ligand due to glycoprotein 130 mutants. [3] [4] [5] 7 A phenotypic classification is based on features of morphology and immunohistochemistry. Close relationships have been found between these molecular subgroups defined by genotype and their clinicopathological characteristics. [3] [4] [5] 7 This new genotype/phenotype subclassification of HCA was introduced by Bioulac-Sage and colleagues and is currently presented by the WHO Tumors of the Digestive System. 1, 5, 7 The HNF 1α biallelic somatic mutation is observed in 35-40% of HCA cases. It almost always occurs in women. HNF 1α-inactivated HCA is most highly steatotic, with a lack of expression of liver fatty acid binding protein (LFABP) in immunohistochemistry analyses. Significant inflammation and cellular atypia are absent. A HNF 1α germline mutation is observed in <5% of HCA cases and can be associated with MODY 3 diabetes, particularly in children and young adults. The diagnosis of HNF 1α-inactivated HCA may be suggested by a radiologist due to the steatosis. The second type, an activating β-catenin mutation, is found in 10-15% HCA cases. This β-catenin activated HCA subtype is often associated with males as in our case or specific conditions (glycogenosis or administration of male hormone). Cytologic atypia and a pseudoglandular growth pattern are frequently observed. Immunohistochemistry studies show that this HCA subtype overexpresses β-catenin (nuclear and cytoplasmic) and GS. Because this group has a higher risk of malignant transformation into HCC than that of other subtypes, identifying β-catenin activated HCA subtype is extremely important. The third, inflammatory HCA, is observed in 45-60% of cases, and most patients with this subtype are women. Lesions are characterized by inflammatory infiltrates, thick-walled arteries, sinusoidal dilatation, and a ductular reaction. Inflammatory HCA is immunohistochemically characterized by increased expression of SAA/CRP at both the mRNA and protein levels. GS is usually absent, and LFABP is normally expressed in the non-tumoral liver parenchyma. GGT is frequently elevated in this group, with a biological inflam- Grading: +, mild; 2+, moderate; 3+, severe; -, absent.
HNF 1a, hepatocyte nuclear factor 1; SAA/CRP, serum amyloid A and C reactive protein; BMI, body mass index; ND, not done.
http://www.e-cmh. 8 Our case showed diffuse and strong positivity for GS and aberrant cytoplasmic and nuclear staining for β-catenin, so the diagnosis of β-cateninactivated HCA was made by immunohistochemistry (Table 1) . However, the present case exhibited some unusual histological features such as diffuse steatosis, inflammatory infiltrates, and peliosis, which usually appear in inflammatory HCA. Therefore, our case should be distinguished from β-catenin-activated inflammatory HCA. Steatosis and inflammation are usually absent in β-catenin-activated HCA. 1, 5, 7, 9 However, Bordeaux's group has pointed out that β-catenin-activated HCA and inflammatory HCA have overlapping features of an inflammatory infiltrate, patchy steatosis, diffuse GS staining, and β-catenin mutation. 3 Inflammatory HCA is characterized by diffuse, strong expression of SAA or CRP in tumoral hepatocytes. 1, [3] [4] [5] 7 These markers are useful for distinguishing cases with overlapping histological features. 10 We excluded inflammatory HCA because no SAA/CRP expression was observed, which is necessary for a diagnosis of inflammatory HCA. Despite that radiological imaging techniques have made great progress in identifying benign liver tumors, it is difficult to distinguish between different types of HCA (particularly β-cateninactivated HCA, which has variable and nonspecific radiologic findings). 11 Complete surgical removal and a careful pathological examination are necessary to prevent a potential misdiagnosis and identify β-catenin-activated HCA, which is prone to develop into HCC.
